Search Results

You are looking at 1 - 10 of 177 items for :

  • "irinotecan" x
Clear All
Full access

Joseph Rosales and Lucille A. Leong

and novel analyses from two large, randomised, phase III trials . Br J Cancer 2004 ; 90 : 1190 – 1197 . 6 Saltz LB Cox JV Blanke C . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

Full access

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock and David R. Gandara

metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes . J Clin Invest 1998 ; 101 : 847 – 854 . 25 Ando Y Saka H Ando M

Full access

Benjamin Levy, Ashish Saxena and Bryan J. Schneider

toxicity profile compared with multidrug nonplatinum regimens, and the survival advantage shown in the 2 aforementioned meta-analyses. Etoposide Versus Irinotecan The combination of irinotecan with cisplatin (IP) is also an effective regimen for

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

in the first-line treatment of metastatic colorectal cancer . J Clin Oncol 2009 ; 27 : 663 – 771 . 30 Tejpar S Peeters M Humblet Y . Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 4001 . 37 Van Cutsem E Henning

Full access

Steven S. Brem, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Ennio A. Chiocca, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Larry Junck, Gerald P. Linette, Jay S. Loeffler, Moshe H. Maor, Madison Michael, Paul L. Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, Frank D. Vrionis and Patrick Y. Wen

-line or salvage chemotherapy include combination PCV, 40 cyclophosphamide, 41 and platinum-based regimens. 42 Anaplastic gliomas may also be treated by irinotecan 43 or etoposide. 44 Bevacizumab, an antiangiogenic agent, received accelerated approval

Full access

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook and Christopher Willett

bevacizumab, cetuximab, panitumumab, or irinotecan in adjuvant therapy for nonmetastatic disease outside the setting of a clinical trial. Adenocarcinomas of the small bowel or appendix, for which no NCCN Guidelines exist, may be treated with systemic

Full access

Leonard Saltz

, irinotecan) produce essentially the same outcomes in terms of response rates, time to progression, and overall survival (OS). Dr. Saltz further noted that due to its neurotoxic potential, FOLFOX’s place as the preferred initial regimen in the United States

Full access

Margaret A. Tempero

disease, and (3) adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it. Presenting these updates was Margaret A. Tempero, MD, Professor of Medicine, and Director of the UCSF Pancreas